Progress, Potential, and Possibilities Podcast / Show Dr. Nigel McCracken, Ph.D. - Chief Operating Officer, Virax Biolabs - T-Cell Testing For Detecting Immune Responses & Diagnosing Viral Diseases
Dr. Nigel McCracken, Ph.D. is Chief Operating Officer of Virax Biolabs ( https://www.viraxbiolabs.com/ ), an innovative diagnostics and detection biotech company developing a game-changing T-Cell immunology technology platform to provide early diagnosis for post viral syndromes, and indications associated with chronic inflammation and T cell exhaustion, to enable early treatment interventions. Dr. McCracken brings over 25 years of research & development experience in drug development, within a number of indications, including oncology and infectious disease. Prior to joining Virax, Dr. McCracken was the Chief Scientific Officer at BerGenBio AsA where he drove the plan for BerGenBio AsA’s companion diagnostics and assay development. Prior to that role, he served as COO at NuCana PLC, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, where he provided oversight and direction to the operations of the business, research and development and execution of corporate strategy. Dr. McCracken also spent time over his career at major biopharma companies including Debiopharma, Shire, Nycomed, and Abbott. Dr. McCracken obtained a Master’s degree in Clinical Pharmacology from Kings College London, a Doctor of Philosophy degree in Biochemical Toxicology from the University of Newcastle Upon Tyne, and a Bachelor of Science degree in Biochemistry and Pharmacology from Strathclyde University.